


Kenya

Region: East Africa

Key information on co-financing

- Gross National Income per capita (2017): \$ 1,440
- Co-financing status (2019): Preparatory transition phase
- Country is projected to enter accelerated transition phase in 2022
- Country co-financing is aligned to its fiscal year, Kenya is expected to pay its co-financing for July to June period.




Immunisation financing

	2013	2014	2015	2016	2017
Vaccines used in routine immunisation					
- Government expenditure	\$ 4,277,138	\$ 5,133,400	\$ 4,150,000	\$ 7,824,000	\$ 7,824,000
- Total expenditure	\$ 27,727,538	\$ 34,220,900	\$ 43,139,000	\$ 33,880,000	\$ 33,880,000
- Government as % of total	15%	15%	10%	23%	23%
Routine immunisation					
- Government expenditure	\$ 5,739,293	\$ 5,311,200	\$ 4,150,000	\$ 7,824,000	
- Total expenditure	\$ 39,255,293	\$ 38,417,200			\$ 33,925,639
- Government as % of total	15%	14%	N/A	N/A	N/A

Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General Government Health Expenditure (GGHE-D) as a % of General Government Expenditure (GGE) **6%**

Source: WHO National Health Accounts, 2015



Gavi supported vaccines

Vaccines	Type	Year(s) of Gavi support	Co-financing required
Pentavalent	Routine	2001 - present	Yes
PCV	Routine	2011 - present	Yes
IPV	Routine	2015 - present	No
Rotavirus	Routine	2014 - present	Yes
Yellow Fever	Routine	2001 - present	Yes
HPV	Demonstration	2013 - 2015	No
Measles - Rubella	Campaign	2016	No

Co-financing payments

	Total amount paid by the country	Co-financed vaccines	
2008	\$ 1,979,000	Penta	Yellow Fever
2009	\$ 1,652,000	Penta	Yellow Fever
2010	\$ 1,850,000	Penta	Yellow Fever
2011	\$ 2,307,000	Penta	Yellow Fever PCV
2012	\$ 3,136,000	Penta	Yellow Fever PCV
2013	\$ 2,726,000	Penta	Yellow Fever PCV
2014	\$ 2,277,000	Penta	Yellow Fever PCV Rota
2015	\$ 3,887,000	Penta	Yellow Fever PCV Rota
2016-2017	\$ 1,690,236	Penta	Yellow Fever PCV Rota
2017-2018	\$ 2,844,000	Penta	Yellow Fever PCV Rota

Note: Country started co-financing Penta and Yellow fever in 2008.


Co-financing obligations for 2018-2019 (due in June 2019)

	Co-financing obligations (in US\$)	Country dose obligation
PCV	\$ 308,500	99,600
Pentavalent	\$ 324,500	403,000
Rota	\$ 305,500	147,000
YF	\$ 1,000	600
Total	\$ 939,500	

Co-financing obligations for 2019-2020 (due in June 2020)

	Co-financing obligations (in US\$)	Country dose obligation
PCV	\$ 1,002,500	322,000
Pentavalent	\$ 215,000	291,500
Rota	\$ 550,000	238,500
YF	\$ 44,000	35,500
HPV	\$ 658,500	143,100
MR follow up campaign	\$ 262,500	402,600
Total	\$ 2,732,500	

Co-financing projections 2020-2024



	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
Penta	\$ 310,681	\$ 368,484	\$ 434,607	\$ 1,000,363	\$ 1,593,297
PCV	\$ 1,097,800	\$ 1,302,146	\$ 1,534,823	\$ 3,533,807	\$ 5,628,817
Rota	\$ 579,244	\$ 686,893	\$ 809,384	\$ 1,863,138	\$ 2,967,015
YF routine	\$ 24,274	\$ 32,034	\$ 41,713	\$ 104,903	\$ 180,844
HPV National	\$ 458,771	\$ 538,239	\$ 504,282	\$ 810,864	\$ 1,285,560
Total	\$ 2,470,769	\$ 2,927,796	\$ 3,324,809	\$ 7,313,075	\$ 11,655,533

- Projections are based on Gavi's operational forecast version 16.
- Country has been approved for HPV support in 2019-2020.
- These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.